Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy

Only a subgroup of patients with muscle-invasive bladder cancer (MIBC) are responders toward cisplatin-based chemotherapy and PD-L1 blockade immunotherapy. There is a clinical need to identify MIBC molecular subtypes and biomarkers for patient stratification toward the therapies. Here, we performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Qianxing, Li, Roger, Adeegbe, Dennis O., Peng, Guang, Chan, Keith Syson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746703/
https://www.ncbi.nlm.nih.gov/pubmed/33335285
http://dx.doi.org/10.1038/s42003-020-01491-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746703/
https://www.ncbi.nlm.nih.gov/pubmed/33335285
http://dx.doi.org/10.1038/s42003-020-01491-2

Ejemplares similares